Funding for this research was provided by:
American Academy of Neurology / American Brain Foundation (Clinical Research Training Fellowship)
Text and Data Mining valid from 2019-02-11
Received: 14 November 2018
Revised: 2 February 2019
Accepted: 5 February 2019
First Online: 11 February 2019
Compliance with ethical standards
: All the procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all the individual participants included in the study.
: On behalf of all the authors, the corresponding author states that there are no conflicts of interest. Dr. Blattner has no disclosures to report. Dr. de Bruin has equity in Neuroquestions, LLC. Dr. Bucelli receives an annual gift from a patient’s family for Parsonage-Turner research; served on an advisory board for MT Pharma; and has equity in Neuroquestions, LLC. Dr. Day has served as a topic editor on dementia for DynaMed Plus (EBSCO Industries, Inc) and as clinical director for the Anti-NMDA Receptor Encephalitis Foundation (uncompensated). He receives research/grant support from The American Academy of Neurology/American Brain Foundation, Avid Radiopharmaceuticals, the Foundation for Barnes Jewish Hospital, and the National Institutes of Health (P01AG03991, R56AG057195, U01AG057195) and holds stock in ANI Pharmaceuticals, Inc. Dr. Day has provided record review and expert medical testimony on legal cases pertaining to the management of Wernicke encephalopathy.